[1] TORRE L A,BRAY F,SIEGEL R L,et al. Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108. [2] CHEN W,ZHENG R,BAADE P D,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132. [3] DAY C P,MERLINO G,VAN DYKE T. Preclinical mouse cancer models:a maze of opportunities and challenges[J]. Cell,2015,163(1):39-53. [4] TENTLER J J,TAN A C,WEEKES C D,et al. Patient-derived tumour xenografts as models for oncology drug development[J]. Nat Rev Clin Oncol,2012,9(6):338-350. [5] HIDALGO M,AMANT F,BIANKIN A V,et al. Patient-derived xenograft models:an emerging platform for translational cancer research[J]. Cancer Discov,2014,4(9):998-1013. [6] FICHTNER I,ROLFF J,SOONG R,et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers[J]. Clin Cancer Res,2008,14(20):6456-6468. [7] JOHN T,KOHLER D,PINTILIE M,et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer[J]. Clin Cancer Res,2011,17(1):134-141. [8] 罗朋. 人肺鳞癌组织在裸鼠体内的移植成瘤性与其Ki-67表达水平的关系[J]. 肿瘤,2014,10(34):913-918. [9] 卓莹. 荷人肺癌小鼠皮下移植瘤模型的建立及其生物学特性初探[J]. 中国肺癌杂志,2010,6(13):568-574. [10] NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines)[EB/OL]. (2017-07-03). https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. [11] ILIE M,NUNES M,BLOT L,et al. Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps[J]. Cancer Med,2015,4(2):201-211. [12] WANG D,PHAM N A,TONG J,et al. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors[J]. Int J Cancer,2017,140(3):662-673. [13] 秦川,张连峰,魏泓,等. 实验动物学[M]. 北京:人民卫生出版社,2010:42. |